217 related articles for article (PubMed ID: 26923333)
1. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
[TBL] [Abstract][Full Text] [Related]
2. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
3. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
4. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
6. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
9. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
Kang SM; Kang HJ; Shin JH; Kim H; Shin DH; Kim SK; Kim JH; Chung KY; Kim SK; Chang J
Cancer; 2007 Feb; 109(3):581-7. PubMed ID: 17186532
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
11. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
13. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
[No Abstract] [Full Text] [Related]
14. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
15. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
16. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
17. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
[TBL] [Abstract][Full Text] [Related]
18. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
20. Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.
Huo Z; Wu H; Li J; Li S; Wu S; Liu Y; Luo Y; Cao J; Zeng X; Liang Z
PLoS One; 2015; 10(11):e0143169. PubMed ID: 26575266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
